Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: CNS tumours

287MO - A phase 0 ‘trigger’ trial of pamiparib in newly diagnosed and recurrent glioblastoma patients


10 Sep 2022


Mini Oral session: CNS tumours


Targeted Therapy;  Radiation Oncology

Tumour Site

Central Nervous System Malignancies


Nader Sanai


Annals of Oncology (2022) 33 (suppl_7): S122-S135. 10.1016/annonc/annonc1047


N. Sanai1, S.N. Mehta1, Y. Chang1, J. Jiang2, J. Molloy1, C. Pennington-Krygier1, J. Harmon1, A. Hong1, J. Wanebo3, W.(. Kennedy3, M. Garcia3, I. Barani4, W. Yoo1, A. Tovmasyan1, A. Tien5, J. Li2

Author affiliations

  • 1 Ivy Brain Tumor Center, Barrow Neurological Institute, 85013 - Phoenix/US
  • 2 Pharmacology And Metabolomics Core, Wayne State University School of Medicine; Barbara Ann Karmanos Cancer Institute, 48201 - Detroit/US
  • 3 Barrow Brain And Spine, Barrow Neurological Institute, 85013 - Phoenix/US
  • 4 Stereotactic Radiosurgery, Barrow Neurological Institute, 85013 - Phoenix/US
  • 5 Ivy Brain Tumor Center, Barrow Brain and Spine, 85013   - Phoenix/US


Login to access the resources on OncologyPRO.

Abstract 287MO


This phase 0 study evaluates glioblastoma (GBM) pharmacokinetics (PK) and pharmacodynamics (PD) of pamiparib, a PARP1/2-selective inhibitor, graduating patients to a therapeutic expansion phase of drug plus radiotherapy when high unbound drug concentrations are present in nonenhancing tumor.


Newly-diagnosed (Arm A) and recurrent GBM (Arm B) patients received 4 days of pamiparib (60 mg BID) prior to planned resection at 2-4 or 8-12 hours following the final dose. Arm C included recurrent GBM patients who received 4 days of olaparib (200 mg BID). Tumor tissue (enhancing and nonenhancing regions), cerebrospinal fluid (CSF), and plasma were collected. Total and unbound drug concentrations were measured using validated LC-MS/MS methods. A PK ‘trigger’, defined as unbound drug > 5-fold biochemical IC50 in nonenhancing tumor determined eligibility for the therapeutic expansion phase. PARP inhibition was assessed via 10 Gy ex vivo radiation of tumor tissue and quantification of PAR levels compared to non-radiated control. Newly-diagnosed, MGMT-unmethylated and recurrent GBM patients, irrespective of MGMT-status, exceeding the PK threshold were eligible for an expansion phase of study drug plus radiotherapy followed by maintenance dosing of study drug plus TMZ.


In Arms A (n=20) and B (n=14), the mean unbound concentrations of pamiparib in Gd-nonenhancing tumor region were 171.5 nM and 162.5 nM, respectively and in Arm C (n=4) the mean unbound concentration of olaparib was 11.0 nM. All patients in Arms A and B, but only one in Arm C, exceeded the PK threshold to qualify for the expansion phase of the study. Progression onto the expansion phase occurred in 12/20 (60%), 7/14 (50%), and 1/4 (25%) patients in Arms A, B, and C, respectively. Radiation-induced PAR expression was 2.44 fold in untreated control vs 1.16 in Arm A, 0.82 in Arm B and 1.11 in Arm C patients, respectively. The median progression-free survival was 5.8 (Arm A), 3.1 months (Arm B) (n=6), and 1.9 months (Arm C) (n=1), respectively.


Pamiparib was generally well-tolerated, achieved pharmacologically-relevant concentrations in nonenhancing GBM tissue and suppressed induction of PAR levels ex vivo post-radiation.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Nader Sanai, St. Joseph's Hospital and Medical Center, Phoenix.


Ivy Brain Tumor Center at Barrow Neurological Institute, Phoenix, AZ.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.